Physician profile
Orest Stecyk
NPI 1063453611
$703.25
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.29 · 2021: $24.68 · 2023: $217 · 2024: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $636.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $107.82 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $86.77 | 2021-2024 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $76.50 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $66.69 | 2023-2024 | Mounjaro, Zepbound |
| Abbvie INC. | $63.87 | 2023-2024 | Ubrelvy, Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $55.44 | 2023-2024 | |
| Sunovion Pharmaceuticals INC. | $42.29 | 2019 | |
| Pfizer INC. | $42.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $32.97 | 2023 | |
| Xeris Pharmaceuticals, INC. | $21.24 | 2024 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $17.08 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $16.71 | 2024 | Camzyos |
| Astellas Pharma US INC | $16.31 | 2023 | Veozah |
| Abbott Laboratories | $15.79 | 2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $15.05 | 2024 | Gardasil, Gardasil 9 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $13.43 | 2024 | Voquezna |
| Lundbeck LLC | $13.29 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orest Stecyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.